NASDAQ: SKYESkye Bioscience Inc Stock
$1.57+0.13 (+9.03%)
Updated Apr 21, 2025
SKYE Price
$1.57
Fair Value Price
N/A
Market Cap
$48.63M
52 Week Low
$1.14
52 Week High
$15.60
P/E
-2.15x
P/B
0.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$26.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$25M
Beta
129.55
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SKYE Overview
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SKYE's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SKYE
Ranked#400 of 462
Ranked#400 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important SKYE news, forecast changes, insider trades & much more!
SKYE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SKYE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKYE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SKYE is good value based on its book value relative to its share price (0.71x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
SKYE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SKYE due diligence checks available for Premium users.
Valuation
SKYE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.15x
Industry
-184.27x
Market
27.14x
SKYE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
4.04x
SKYE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKYE's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.7M
Profit Margin
0%
SKYE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$72.8M
Liabilities
$4.6M
Debt to equity
0.07
SKYE's short-term assets ($70.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKYE's short-term assets ($70.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKYE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SKYE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
$90.4k
Financing
$5.6k
SKYE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SKYE vs Biotech Stocks
Skye Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.